Start4559 • TYO
add
Zeria Pharmaceutical Co Ltd
Seneste lukkekurs
2.244,00 ¥
Dagsinterval
2.247,00 ¥ - 2.274,00 ¥
Årsinterval
1.921,00 ¥ - 2.411,00 ¥
Markedsværdi
119,94 mia. JPY
Gns. volumen
63,62 t
P/E-værdi
11,86
Udbytteprocent
1,99 %
Primær børs
TYO
Markedsnyheder
Økonomi
Resultatopgørelse
Indtægt
Nettoindtægt
(JPY) | sep. 2024info | År til år-ændring |
---|---|---|
Indtægt | 20,97 mia. | 14,11 % |
Driftsudgifter | 12,52 mia. | 14,20 % |
Nettoindtægt | 1,85 mia. | -25,47 % |
Overskudsgrad | 8,82 | -34,67 % |
Earnings per share | — | — |
EBITDA | 4,39 mia. | 8,29 % |
Effektiv afgiftssats | 17,59 % | — |
Årsbalance
Samlede aktiver
Samlede passiver
(JPY) | sep. 2024info | År til år-ændring |
---|---|---|
Kontanter og korttidsinvesteringer | 24,36 mia. | 31,90 % |
Samlede aktiver | 158,34 mia. | 6,87 % |
Samlede passiver | 69,77 mia. | -3,36 % |
Samlet egenkapital | 88,57 mia. | — |
Shares outstanding | 44,08 mio. | — |
Kurs/indre værdi | 1,12 | — |
Afkast af aktiver | 4,06 % | — |
Afkast af kapital | 4,89 % | — |
Pengestrøm
Nettoændring i likviditet
(JPY) | sep. 2024info | År til år-ændring |
---|---|---|
Nettoindtægt | 1,85 mia. | -25,47 % |
Pengestrøm fra drift | — | — |
Pengestrøm fra investering | — | — |
Pengestrøm fra finansiering | — | — |
Nettoændring i likviditet | — | — |
Fri pengestrøm | — | — |
Om
Zeria Shinyaku Kōgyō KK is a Japanese drug manufacturer that obtained Tillotts Pharma AG.
In 1955, the Japanese Kisaku Ibu, former Yamanouchi Seiyaku executive opened a new pharmaceutical company in Tokyo under the name Zeria Yakushō Kenkyusho. In 1970, this company becomes Zeria Shinyaku Zeria Shinyaku KK.
In 1975, it built a new factory in Kumagaya in Saitama prefecture, before the main factory in Tsukuba which was constructed by Takenaka Corporation in 1988.
In 2009, the company obtained Switzerland company Tillotts Pharma AG, and began operating internationally through a large network of subsidiaries,
It manufactures and sells pharmaceuticals in Sweden, Ireland, UK, Czech Republic, Spain, Germany, France, Italy, Vietnam and Denmark. The drug itself is developed in Switzerland, Tillotts Parma.
The company owns a 6.63% share of Asuka Seiyaku, also a pharmaceutical company, other than its subsidiaries.
The main shareholder of the company is the company itself, the present president Mitsuhiro Ibu, Mitsubishi UFJ Financial Group, Custody Bank of Japan, Morinaga Milk Industry, SMBC, Mizuho Bank, Risona Bank, Aioi Nissay Dowa Insurance as of March 2023. Wikipedia
Administrerende direktør
Grundlagt
22. dec. 1955
Website
Ansatte
1.777